# Optimal Blood Pressure and Cholesterol Targets for Preventing Recurrent Stroke in Hypertensives

Study · id `cardio:ct-nct01563731` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01563731](<https://clinicaltrials.gov/study/NCT01563731>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01563731

Browse, organ or system: Heart; Blood vessels; Brain  
Browse, condition area: High blood pressure; Coronary and vascular disease; Stroke; Heart failure; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.

## Technical summary

Registry record NCT01563731. Randomized; no masking; primary purpose prevention. Start 2013-04 (actual); primary completion 2020-12-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 200 participants (enrolled count; ClinicalTrials.gov record NCT01563731, source copy `cardio:ctgov-nct01563731-2024-02-20`, retrieved 2026-10-26)
- Started: 2013-04 (actual) (ClinicalTrials.gov record NCT01563731, source copy `cardio:ctgov-nct01563731-2024-02-20`, retrieved 2026-10-26)
- Primary completion: 2020-12-31 (actual) (ClinicalTrials.gov record NCT01563731, source copy `cardio:ctgov-nct01563731-2024-02-20`, retrieved 2026-10-26)
- Completion: 2021-03-31 (actual) (ClinicalTrials.gov record NCT01563731, source copy `cardio:ctgov-nct01563731-2024-02-20`, retrieved 2026-10-26)
- Countries: Russia (ClinicalTrials.gov record NCT01563731, source copy `cardio:ctgov-nct01563731-2024-02-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01563731-2024-02-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Optimal Blood Pressure and Cholesterol Targets for Preventing Recurrent Stroke in Hypertensives
- Acronym: ESH-CHL-SHOT
- Condition: Stroke
- Condition: Transient Ischemic Attack
- Condition: Hypertension
- Intervention (Drug): all approved antihypertensive drugs; all approved statins
- Lead sponsor: Istituto Auxologico Italiano
- Lead sponsor class: OTHER
- Collaborator: European Society of Hypertension
- Collaborator class: OTHER
- Collaborator: Chinese Hypertension League
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Transient ischemic attack (mini-stroke) (`cardio:transient-ischemic-attack`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Istituto Auxologico Italiano (`cardio:org-istituto-auxologico-italiano`)

## Provenance

Content hash: 80f01545bfb7eaae5ae544aa4f842ba10ade8d297faa3cc14b66969ce2a87c67
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
